idecabtagene vicleucel

Details

Files

Generic Name:

Project Status:

Complete

Therapeutic Area:

Multiple myeloma

Manufacturer:

Celgene Inc., a Bristol Myers Squibb company

Brand Name:

Abecma

Project Line:

Reimbursement Review

Project Number:

PG0240-000

Tumour Type:

Myeloma

NOC Status at Filing:

Pre NOC

Performance Metric:

Achieved

Biosimilar:

Manufacturer Requested Reimbursement Criteria¹:

For the treatment of adult patients with multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and who are refractory to their last treatment.

Submission Type:

Initial

Fee Schedule:

Schedule E

Indications:

Recommendation Type:

Do not reimburse

Final Recommendation:

November 12, 2021

The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.

Key Milestones²
Call for patient/clinician input open	18-Nov-20
Call for patient/clinician input closed	15-Jan-21
Clarification: - Patient input submission received from Myeloma Canada
Submission received	16-Dec-20
Submission accepted	07-Jan-21
Review initiated	08-Jan-21
Draft CADTH review report(s) provided to sponsor for comment	26-Mar-21
Deadline for sponsors comments	07-Apr-21
CADTH responses on draft review report(s) provided to sponsor	03-May-21
Expert committee meeting (initial)	14-May-21
Draft recommendation issued to sponsor	04-Jun-21
Draft recommendation posted for stakeholder feedback	17-Jun-21
End of feedback period	02-Jul-21
Clarification: - Reconsideration: major revisions requested by sponsor
Expert committee meeting	13-Oct-21
Final recommendation issued to sponsor and drug plans	27-Oct-21
Final recommendation posted	12-Nov-21
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)	10-Nov-21
CADTH review report(s) posted	02-Feb-22